Cidara Therapeutics (CDTX) Stock Forecast & Price Target

$20.21 +0.01 (+0.05%)

(As of 11/29/2024 ET)

Cidara Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 5 Analyst Ratings

Sell
0

Hold
0

Buy
5

Based on 5 Wall Street analysts who have issued ratings for Cidara Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 4 have given a buy rating, and 1 has given a strong buy rating for CDTX.

Consensus Price Target

$30.50
50.92% Upside

According to the 5 analysts' twelve-month price targets for Cidara Therapeutics, the average price target is $30.50. The highest price target for CDTX is $40.00, while the lowest price target for CDTX is $24.00. The average price target represents a forecasted upside of 50.92% from the current price of $20.21.

Get the Latest News and Ratings for CDTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cidara Therapeutics and its competitors.

CDTX Analyst Ratings Over Time

Type	Current Forecast 12/1/23 to 11/30/24	1 Month Ago 11/1/23 to 10/31/24	3 Months Ago 9/2/23 to 9/1/24	1 Year Ago 12/1/22 to 12/1/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$30.50	$29.67	$29.67	$93.33
Forecasted Upside	50.92% Upside	128.21% Upside	149.51% Upside	497.60% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Paypal, Tesla, SpaceX… Elon's next project is bigger than them all (Ad)

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

CDTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CDTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cidara Therapeutics Stock vs. The Competition

Type	Cidara Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.20	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	50.92% Upside	25,353.18% Upside	6.49% Upside
News Sentiment Rating	Neutral News See Recent CDTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	HC Wainwright 2 of 5 stars	E. Arce Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00	+77.78%
11/8/2024	Guggenheim 2 of 5 stars	S. Fernandez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$33.00	+151.72%
8/14/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight
8/14/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00	+105.76%
4/25/2024	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Strong-Buy ➝ Strong-Buy	$40.00	+207.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:28 AM ET.

CDTX Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Cidara Therapeutics is $30.50, with a high forecast of $40.00 and a low forecast of $24.00.
: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDTX shares.
: According to analysts, Cidara Therapeutics's stock has a predicted upside of 50.92% based on their 12-month stock forecasts.
: Cidara Therapeutics has been rated by research analysts at Guggenheim, and HC Wainwright in the past 90 days.
: Analysts like Cidara Therapeutics more than other "medical" companies. The consensus rating for Cidara Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CDTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Paypal, Tesla, SpaceX… Elon's next project is bigger than them all (Ad)

So please click here to see the details because a lot of people could get rich.

This page (NASDAQ:CDTX) was last updated on 11/30/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cidara Therapeutics (CDTX) Stock Forecast & Price Target